ADMA Biologics Stock Forecast, Price & News

-0.03 (-1.62 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.24 million shs
Average Volume5.70 million shs
Market Capitalization$233.31 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Biologics logo

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.59 out of 5 stars

Medical Sector

452nd out of 2,096 stocks

Biological Products, Except Diagnostic Industry

55th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

Is ADMA Biologics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than ADMA Biologics?

Wall Street analysts have given ADMA Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADMA Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ADMA Biologics

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly earnings results on Tuesday, May, 11th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $16.05 million for the quarter, compared to the consensus estimate of $15.63 million. ADMA Biologics had a negative trailing twelve-month return on equity of 85.82% and a negative net margin of 155.78%.
View ADMA Biologics' earnings history

How has ADMA Biologics' stock been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADMA stock has decreased by 21.2% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2024 After-Hours earnings guidance on Thursday, March, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million.

What price target have analysts set for ADMA?

5 analysts have issued 1 year price objectives for ADMA Biologics' shares. Their forecasts range from $6.00 to $11.00. On average, they anticipate ADMA Biologics' stock price to reach $7.80 in the next year. This suggests a possible upside of 328.6% from the stock's current price.
View analysts' price targets for ADMA Biologics
or view top-rated stocks among Wall Street analysts.

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 44, Pay $1.13M)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 73, Pay $70.9k)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 49, Pay $802.87k)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 75, Pay $911.2k)
  • Ms. Kim Tripodo, Exec. Director & Head of Human Resource and Admin. Operations
  • Mr. Skyler Bloom, Director of Investor Relations & Corp. Strategy
  • Ms. Kaitlin Kestenberg, VP of Compliance, Project Management & Clinical Operations
  • Mr. Michael Goldstein, Sr. Director & Gen. Counsel
  • Mr. Michael Least, VP of Sales & Commercial Operations
  • Mr. Drew Pantello, VP of Marketing & Corp. Devel.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (5.57%), BlackRock Inc. (4.74%), Geode Capital Management LLC (1.12%), Northern Trust Corp (0.65%), Schonfeld Strategic Advisors LLC (0.57%) and Squarepoint Ops LLC (0.47%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics

Which institutional investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Prosight Management LP, Alyeska Investment Group L.P., Thrivent Financial for Lutherans, Northern Trust Corp, Los Angeles Capital Management LLC, New York Life Investments Alternatives, and AE Wealth Management LLC.
View insider buying and selling activity for ADMA Biologics
or view top insider-selling stocks.

Which institutional investors are buying ADMA Biologics stock?

ADMA stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, Geode Capital Management LLC, Clearline Capital LP, BlackRock Inc., GSA Capital Partners LLP, Morgan Stanley, and Barclays PLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics
or or view top insider-buying stocks.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $1.82.

How much money does ADMA Biologics make?

ADMA Biologics has a market capitalization of $233.31 million and generates $42.22 million in revenue each year. The biotechnology company earns $-75,750,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does ADMA Biologics have?

ADMA Biologics employs 406 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is

Where are ADMA Biologics' headquarters?

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.